Find Funding Opportunities

This Funding Opportunity Announcement (FOA) issued by the Office of Research on Women's Health (ORWH) and co-sponsoring Institutes and Centers (ICs) of the National Institutes of Health (NIH) encourages investigator(s)-initiated applications that propose to examine the etiology, diagnosis, pathophysiology, and treatment of chronic fatigue syndrome (CFS), sometimes referred to as myalgic encephalomyelitis (ME), in diverse groups and across the lifespan. Applications that address gaps in the understanding of the environmental and biological risk factors, the determinants of heterogeneity among patient populations, the common mechanisms influencing the multiple body systems that are affected in ME/CFS are encouraged. The NIH is particularly interested in funding interdisciplinary research that will enhance our knowledge of the disease process and provide evidence based solutions to improve the diagnosis, treatment, and quality of life of all persons with ME/CFS. This interdisciplinary research may include the building of scientific teams to study and develop biomarkers, innovative treatment modalities, and/or the modifiable risk and protective processes specifically targeted by preventive and/or treatment interventions.

This Funding Opportunity Announcement (FOA) issued by the Office of Research on Women's Health (ORWH) and co-sponsoring Institutes and Centers (ICs) of the National Institutes of Health (NIH) encourages investigator(s)-initiated applications that propose to examine the etiology, diagnosis, pathophysiology, and treatment of chronic fatigue syndrome (CFS), sometimes referred to as myalgic encephalomyelitis (ME), in diverse groups and across the lifespan. Applications that address gaps in the understanding of the environmental and biological risk factors, the determinants of heterogeneity among patient populations, the common mechanisms influencing the multiple body systems that are affected in ME/CFS are encouraged. The NIH is particularly interested in funding interdisciplinary research that will enhance our knowledge of the disease process and provide evidence based solutions to improve the diagnosis, treatment, and quality of life of all persons with ME/CFS.

The program offers the opportunity for a unique bridge between the NIH intramural and extramural research communities, and contains two phases. In the first phase, Lasker scholars will receive appointments for up to 5-7 years as tenure-track investigators within the NIH Intramural Research Program with independent research budgets. In the second phase, successful scholars will be eligible to apply for up to 5 years of NIH support for their research at an extramural research facility; or, the scholar can be considered to remain as an investigator within the intramural program.

The purpose of the Academic Research Enhancement Award (AREA) program is to stimulate research in educational institutions that provide baccalaureate or advanced degrees for a significant number of the Nation's research scientists, but that have not been major recipients of NIH support. AREA grants create opportunities for scientists and institutions, otherwise unlikely to participate extensively in NIH research programs, to contribute to the Nation's biomedical and behavioral research effort. AREA grants are intended to support small-scale research projects proposed by faculty members of eligible, domestic institutions, to expose students to meritorious research projects, and to strengthen the research environment of the applicant institution.

This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for projects to transfer technology out of the NIH intramural research labs into the private sector. If selected for SBIR funding, the SBC will be granted a royalty-free, non-exclusive internal research-use license for the term of and within the field of use of the SBIR award to technologies held by NIH with the intent that the SBC will develop the invention into a commercial product to benefit the public.

This Funding Opportunity Announcement (FOA) issued by the NIH Basic Behavioral and Social Sciences Opportunity Network (OppNet) solicits Research Project grant (R01) applications from institutions and organizations that propose to investigate basic psychological, social, and environmental mechanisms and processes linking psychosocial stressors and behavior. This FOA will facilitate investigation of multiple and potentially bidirectional pathways underlying the behavioral, environmental, and psychosocial link(s) between psychosocial stressors and behaviors that may ultimately impact biological function, health, and disease. Applicants are encouraged to use innovative and integrative designs to elucidate how psychological, social, and psychosocial environmental factors impact the processes by which stressors become coupled with and influenced by behaviors. Applications examining moderating factors such as individual demographic (age, gender/sex, ethnicity) and psychological (vulnerabilities, resilience) differences, risk factors, timing of exposure to stressors, and environments are desirable. This research will provide a deeper understanding of the psychological, environmental, and social processes that ultimately connect psychosocial stress and behaviors and consequently physiological processes, health, and disease.

This FOA encourages applications for biomarker validation trials or exploratory clinical trials of drugs, biologics, surgical therapies or devices that may contribute to the justification for and provide the data required to design a future trial to confirm efficacy (i.e., a Phase III trial) in the treatment of neurologic disease. Applications for drugs or biologics should provide compelling scientific evidence that the investigational agent proposed for study will reach/act upon the designated target or that its mechanism of action is such that it will be of benefit in ameliorating a specific aspect of the disease. Diseases chosen for study should be based on the NINDS' strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm). Successful applicants will be given access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol. Applicants do not need to be part of the existing NeuroNEXT infrastructure.

This FOA encourages proposals for biomarker validation trials or exploratory clinical trials of drugs, biologics, surgical therapies or devices that may contribute to the justification for and provide the data required to design a future trial to confirm efficacy (i.e., a Phase III trial) in the treatment of neurologic disease. Proposals for drugs or biologics should provide compelling scientific evidence that the investigational agent proposed for study will reach/act upon the designated target or that its mechanism of action is such that it will be of benefit in ameliorating a specific aspect of the disease.

This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose biomarker validation trials or exploratory clinical trials of drugs, biologics, surgical therapies or devices for neurological disorders which may contribute to the justification for and provide the data required to design a future trial to confirm efficacy (i.e., a Phase III clinical trial) in the treatment of neurologic disease. The program will utilize the cooperative agreement mechanism to enable milestone-drive projects.

The purpose of this funding opportunity announcement (FOA), issued by NINDS, is to invite new and renewal applications to participate as Clinical Site Hubs in the Neurological Emergencies Treatment Trials (NETT) Network.The goal of this existing network is to develop and widely implement efficacious treatments for patients with a broad spectrum of neurological emergencies in order to decrease the morbidity and mortality associated with neurological disease.Their objective is to conduct multiple, large, streamlined phase III clinical trials involving neurological emergencies.